Vistagen to Present at Jefferies 2023 Global Healthcare Conference
06 Junho 2023 - 5:30PM
Business Wire
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced that its Chief Executive Officer,
Shawn Singh, will present and host one-on-one meetings at the
Jefferies Global Healthcare Conference taking place June 7 – 9,
2023 in New York City, NY.
Jefferies 2023 Global Healthcare Conference Details
Fireside Chat Date and Time: Friday, June 9 at 9:30 a.m. Eastern
Time Location: Marriott Marquis in New York City, NY
Investors interested in arranging a one-on-one meeting during
the conference should contact the Jefferies Global Healthcare
Conference coordinator.
About Jefferies Global Healthcare Conference
The annual gathering of over 500 public & private healthcare
companies and 3,000 leading executives, institutional investors,
private equity investors & VCs will address near- and long-term
investment opportunities and discuss the current trends driving
healthcare in the U.S. and internationally.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available for
treatment of anxiety, depression and multiple CNS disorders.
Vistagen’s pipeline includes six clinical-stage product candidates,
including five investigational agents belonging to a new class of
drugs known as pherines, in addition to AV-101, an oral prodrug of
7-Cl-CYNA, which is a full antagonist of the glycine site of the
N-methyl-D-aspartate receptor (NMDAR), inhibiting activity of the
ion channel of the NMDAR but not blocking it. Pherines, which are
administered as nasal sprays, are designed with an innovative
rapid-onset mechanism of action that activates chemosensory neurons
in the nasal passages and can selectively and beneficially impact
key neural circuits in the brain without requiring systemic uptake
or direct activity on CNS neurons. Vistagen is passionate about
transforming mental health care and redefining what is possible in
the treatment of anxiety, depression and several other CNS
disorders. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230606006038/en/
Investors: Mark McPartland Senior Vice President, Investor
Relations (650) 577-3606 markmcp@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024